BioSpace News Archive

The KIC Washington Center will continuously support the domestic biotech company’s entry into the U.S. market.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients. The study, named ESCAPE (Nº EudraCT: 2020-001618-39), is an open-label, randomized, double arm Phas

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that pending the receipt of additional information from the Company, Nasdaq has halted the trading in the Company’s common stock.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic derm

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Thursday, May 21, 2020, at 8:30 a.m. ET to review its first quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors” section of the Gamida Cell websit

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced the results of a health economic outcomes study demonstrating that the therapeutic benefit of increasing the use of novel medicines is so great that it is driving a decrease in the actual total cost of healthcare.

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer (NSCLC). Now, physicians will be able to use the PD-L1 IHC 28-8 pharmDx assay as an aid in identifying patients with metastatic NSCLC

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 at 2:30 pm Eastern Time. Interested investors can access the live presentation as part of the Solebury Trout

Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the c